- Home
- FMS vs MRNA Comparison
FMS vs MRNA Comparison
Compare FMS & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMS
- MRNA
- Stock Information
- Founded
- FMS 1996
- MRNA 2010
- Country
- FMS Germany
- MRNA United States
- Employees
- FMS N/A
- MRNA N/A
- Industry
- FMS Misc Health and Biotechnology Services
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FMS Health Care
- MRNA Health Care
- Exchange
- FMS Nasdaq
- MRNA Nasdaq
- Market Cap
- FMS 13.4B
- MRNA 16.0B
- IPO Year
- FMS 1996
- MRNA 2018
- Fundamental
- Price
- FMS $24.59
- MRNA $35.12
- Analyst Decision
- FMS Hold
- MRNA Hold
- Analyst Count
- FMS 1
- MRNA 20
- Target Price
- FMS $25.00
- MRNA $67.06
- AVG Volume (30 Days)
- FMS 240.9K
- MRNA 13.0M
- Earning Date
- FMS 02-25-2025
- MRNA 02-14-2025
- Dividend Yield
- FMS 2.58%
- MRNA N/A
- EPS Growth
- FMS 46.47
- MRNA N/A
- EPS
- FMS 2.50
- MRNA N/A
- Revenue
- FMS $21,457,738,113.00
- MRNA $5,081,000,000.00
- Revenue This Year
- FMS N/A
- MRNA N/A
- Revenue Next Year
- FMS $3.88
- MRNA N/A
- P/E Ratio
- FMS $19.60
- MRNA N/A
- Revenue Growth
- FMS N/A
- MRNA N/A
- 52 Week Low
- FMS $17.93
- MRNA $31.94
- 52 Week High
- FMS $25.25
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- FMS 64.68
- MRNA 40.09
- Support Level
- FMS $24.29
- MRNA $33.84
- Resistance Level
- FMS $25.25
- MRNA $45.15
- Average True Range (ATR)
- FMS 0.33
- MRNA 3.24
- MACD
- FMS 0.10
- MRNA -0.39
- Stochastic Oscillator
- FMS 73.24
- MRNA 11.28
About FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating over 300,000 patients from roughly 3,750 clinics across the globe as of mid-2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.